RAPEX System 2019 Report
Every week, the RAPEX system publishes notifications of urgent measures taken by EU Member-States to prevent, restrict or impose conditions on the marketing of products due to the serious and immediate danger they pose to the health and safety of consumers.
Marta Pinto

Marta Pinto

Regulatory Affairs Associate

RAPEX NETWORK 

In 2005, the European Union (EU) set up the rapid alert system (RAPEX) for dangerous non-food products, based on the General Product Safety Directive (Directive 2001/95/EC). The aim of this system is to accelerate the information exchange and cooperation on product safety. In 2010, this network included also alerts on products posing other risks (other than for health or safety), such as environmental risks, and products exclusively for professional use. Food, pharmaceutical products or medical devices are not included in the RAPEX system. 

Through this system, national authorities (responsible for product safety) are able to send alerts to the European Commission, where they report the measures taken against products posing a risk. After checking all the information reported, the Commission publicly publishes it on the ‘Safety Gate’ website, informing consumers about dangerous products. 

Companies have the responsibility to place safe products on the market and the national authorities need to check if the companies comply with their obligations, conducting regular inspections and sampling of products for testing. The Product Safety Business Alert Gateway is the tool set up by the Commission to facilitate companies reporting. Consumers may also report dangerous products to the national authorities. 

2019 RAPEX REPORT – COSMETICS 

In 2019, there were 2243 alerts received in the system on measures taken against dangerous products. There were 4477 follow-up actions taken by the competent authorities in response to the alerts concerning dangerous products. 

96 cosmetic products (sold in shops or internet) from 27 countries were subject to withdrawal, recall or prohibition of marketing (6% of notifications reported). From these, skin lightening products, perfumes, body care and hair dyes accounted for more than half of the notifications for cosmetics (approximately 56%). Almost 60% of notifications concerning cosmetics are justified by the presence of prohibited ingredients (e.g. MI/MIT, certain colorants, heavy metals, formaldehyde, medicinal substances, hydroquinone), whilst 18.75% are due to microbiological contamination.

National authorities have detected chemicals which can result in serious risks to consumers’ health and safety. For example, in 2019, 10 alerts concerned cosmetic products containing mercury. This metal has the ability to accumulate in the human body, damage the kidneys, brain and nervous system and can affect reproduction. 

Carcinogenicity is a significant hazard that remains amongst the potential health effects. Compared to the previous year, there was a slight decrease in the alerts involving products containing substances which may induce cancer in long term (such as cosmetics, tattoo inks and toys) reported on the Safety Gate (2019). Aromatic amines and nitrosamines, nitrosatable substances, polycyclic aromatic hydrocarbons (which interfere with DNA) and cadmium are among the chemicals commonly detected and that continue a key source of concern.  

Tattoo inks may contain several chemical components that may pose risks to the health of consumers and also to the professionals handling such products. Polycyclic aromatic hydrocarbons, benzo[a]pyrene, cadmium and lead were detected in tattoo inks and can lead to serious health problems.  

Another cause of concern are the products made available online. 16% of the alerts in 2019 mentioned that the dangerous products were sold online. Checking and testing these products can be tricky, especially if the seller is located outside the EU. 

References: 

  1. European Commission – 2019 Results of the Rapid Alert System for dangerous non-food products. Available at: https://ec.europa.eu/consumers/consumers_safety/safety_products/rapex/alerts/repository/content/pages/rapex/reports/docs/RAPEX.2019.report.EN.pdf 
  1. Directive 2001/95/EC of the European Parliament and of the Council of 3 December 2001 on general product safety. Available at: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32001L0095&from=EN 

further
reading

medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »